Article

WaveTec Vision secures additional financing

WaveTec Vision has secured $15.9 million in Series D financing from existing and new investors.

Aliso Viejo, CA-WaveTec Vision has secured $15.9 million in Series D financing from existing and new investors.

The company will use the funds to expand commercialization of its intraoperative wavefront aberrometer (ORange), demonstrate further the clinical efficacy of the technology, and increase its infrastructure, said Tom Frinzi, WaveTec chief executive officer.

The Series D financing was led by existing investor Versant Ventures, with participation from existing investors Accuitive Medical Ventures and De Novo Ventures. New investor Gund Investment Corporation also participated in the funding.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.